LP-184

DRUG2 trials

Sponsors

Region Hovedstaden, Lantern Pharma Inc.

Conditions

Advanced Solid TumorDDR Gene MutationGBMMetastatic Solid TumorNSCLCOncologyPancreatic AdenocarcinomaTNBC - Triple-Negative Breast Cancer

Phase 1

Study of LP-184 in Patients With Advanced Solid Tumors

Active, not recruitingNCT05933265

Lantern Pharma Inc.Advanced Solid Tumor, DDR Gene Mutation, GBM +4

Start: 2023-06-09End: 2026-07-28Updated: 2026-05-04

EXUROC Bladder Target - A phase Ib/ll study to determine the safety, tolerability, and efficacy of LP-184 treatment in patients with advanced/metastatic urothelial carcinoma

Not yet recruitingCTIS2026-525808-94-00

Region HovedstadenOncology

Target: 39Updated: 2026-07-10

Related Papers

A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.

2026-07-07

A first-in-human phase 1a study of LP-184, a tumor site–activated novel alkylating agent, in patients with advanced solid tumors.

Journal of Clinical Oncology2026-05-28

Phase 1a Evaluation of LP-184 in Recurrent Glioblastoma: Safety, Pharmacokinetics, and Translational Optimization of CNS Exposure

medRxiv2026-04-24

Abstract CT116: Data-driven characterization of platelet count and alanine aminotransferase dynamics in the first-in-human LP-184 dose escalation trial

Cancer Research2026-04-17

EXTH-28. Targeting DNA repair mechanisms with spironolactone to enhance LP-184 CNS pharmacodynamics and efficacy

Neuro-Oncology2025-11-01

CTNI-29. A PHASE 1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND OBJECTIVE RESPONSE OF LP-184 ALONE AND IN COMBINATION WITH SPIRONOLACTONE IN IDH WILD TYPE GLIOBLASTOMA AT FIRST PROGRESSION

Neuro-Oncology2024-11-01